Testing New Drug Combination for Plasma Cell Leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed plasma cell leukemia (confirmed by blood test showing 5% or more abnormal plasma cells)
- Had little to no prior cancer treatment (0–1 cycle of initial therapy)
- Age 18–80 years old
- Good enough overall health to tolerate strong medications (ECOG score of 2 or better)
- No severe heart problems, uncontrolled blood pressure, or serious nerve damage
- No allergies to the study drugs (daratumumab, carfilzomib, lenalidomide, or dexamethasone)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
This trial tests a new Car T-cell treatment called CT0596 for patients with plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this therapy can help control the disease in patients who have already tried other treatments.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
This trial tests a new treatment plan for people newly diagnosed with primary plasma cell leukemia (pPCL). It uses two different drug combinations that include daratumumab, given one after the other, followed by maintenance daratumumab. The goal is to see if this approach is safe and works well.
Hear when a new Plasma Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.